Streetbeat News

Price Targets

NVDA

Melius Research has maintained its Buy rating on NVIDIA (NASDAQ:NVDA) and raised the price target from $125 to $160.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2024 | 2:20 pm

NTNX

Morgan Stanley maintains an Equal-Weight rating on Nutanix (NASDAQ:NTNX) but lowers the price target from $72 to $62.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2024 | 2:16 pm

LAZ

Morgan Stanley analyst Ryan Kenny maintains an Overweight rating on Lazard (NYSE:LAZ) but lowers the price target from $58 to $54.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2024 | 2:15 pm

LXRX

HC Wainwright & Co. has reiterated its Buy rating on Lexicon Pharmaceuticals (NASDAQ:LXRX) and maintained a $10 price target, as stated by analyst Joseph Pantginis.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2024 | 2:15 pm

CNTA

Morgan Stanley analyst Matthew Harrison maintains an Equal-Weight rating on Centessa Pharmaceuticals (NASDAQ:CNTA) and raises the price target from $8 to $11.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2024 | 2:14 pm

SWBI

Lake Street analyst Mark Smith maintains a Buy rating on Smith & Wesson Brands (NASDAQ:SWBI) and raises the price target from $16 to $18.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2024 | 2:12 pm

SVCO

B. Riley Securities has reiterated its Buy rating on Silvaco Group (NASDAQ:SVCO) and raised the price target from $26 to $28.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2024 | 2:09 pm

ELUT

Lake Street analyst Frank Takkinen maintains a Buy rating on Elutia (NASDAQ:ELUT) and raises the price target from $5 to $10.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2024 | 2:08 pm

PHAT

Needham analyst Joseph Stringer has reiterated a Buy rating on Phathom Pharmaceuticals (NASDAQ:PHAT) and maintained a $26 price target.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2024 | 2:05 pm